Corpus ID: 6837738

Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.

@article{Spitz2003DeletionsIC,
  title={Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.},
  author={R. Spitz and B. Hero and K. Ernestus and F. Berthold},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 1},
  pages={
          52-8
        }
}
  • R. Spitz, B. Hero, +1 author F. Berthold
  • Published 2003
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
PURPOSE To find new nonrandom chromosomal changes in neuroblastoma (NB) with a potential to forecast the patient's outcome, alterations in chromosome arms 3p and 11q were investigated. EXPERIMENTAL DESIGN Frequency and prognostic potential of 3p and 11q alterations in 144 NBs were analyzed using interphase fluorescence in situ hybridization with DNA probes for 3p26 and 11q23. Aberrations were defined as deletion (monosomy of a specific region) or imbalance (at least two intact and additional… Expand
Loss in Chromosome 11q Identifies Tumors with Increased Risk for Metastatic Relapses in Localized and 4S Neuroblastoma
TLDR
In addition to the current risk stratification, the status of 11q enables the identification of patients with an increased risk for relapse in general and metastatic relapses in particular. Expand
Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
TLDR
Although the most frequent aberration in neuroblastoma to date, it is found that there is no association between 17q gain and an inferior prognosis in this cohort; the status of MYCN and 11q, however, allowed reliable prediction of patients' outcomes. Expand
Molecular cytogenetic analysis of recurrent unbalanced t(11;17) in neuroblastoma.
TLDR
The prevalence of t(11;17) in neuroblastoma warrants additional studies to further define the range in variation in breakpoint positions on both chromosomes and to elucidate the molecular mechanisms that lead to this important and interesting recurrent genetic abnormality. Expand
Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
TLDR
There is a close correlation between amplification of the two genes, amplification of MYCN possibly contributing significantly to the oncogenic properties of AURKA, and the high frequencies of chromosomal aberrations and amplifications of AurKA and MYCN indicate prognostic value in children with neuroblastomas and may point to contributing factors in their development. Expand
Chromosome 17/17q gain and unaltered profiles in high resolution array‐CGH are prognostically informative in neuroblastoma
TLDR
Numerical gain of chromosome 17 is associated with a better prognosis than partial and no gain, and the group of tumors with partial gain was similar to the group without gain with respect to stage distribution, outcome, and gene expression profile. Expand
Distribution of segmental chromosomal alterations in neuroblastoma
TLDR
A small subset of patients with better outcome that share whole-chromosome 19 numeric gain is identified, suggesting its use as a prognostic biomarker in NB. Expand
Oligonucleotide array‐based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome
TLDR
High‐resolution oligonucleotide array‐based comparative genomic hybridization revealed patterns of gains and losses in neuroblastoma of particular importance since several cytogenetic markers proved to be closely associated with the clinical phenotype. Expand
Investigation of major genetic alterations in neuroblastoma
TLDR
Investigating the tumor genetic profile and clinical data of 29 patients with NB by multiplex ligation-dependent probe amplification (MLPA) found 2p, 7q and 17q gains, and 1p and 11q losses as the most frequent chromosome alterations in this cohort. Expand
Chromosome 1p and 11q deletions and outcome in neuroblastoma.
TLDR
Unb11q LOH and 1p36 LOH are independently associated with a worse outcome in patients with neuroblastoma, and both 1p 36 Loh and unb11Q LOH were independently associatedWith decreased progression-free survival in the subgroup of patients with features of low-risk and intermediate-risk disease. Expand
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
TLDR
A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
TLDR
Structural rearrangements resulting in unb[11q] LOH commonly occur during the malignant evolution of high-risk neuroblastomas with single-copy MYCN, and there was only a trend towards an independent prognostic influence in multivariate analyses. Expand
Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
TLDR
Analysis of the results, along with other results reported in the literature, indicate that there is no statistically significant association between 3p and 11q loss and more clinically aggressive tumors. Expand
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
TLDR
Gain of chromosome segment 17q21-qter is an important prognostic factor in children with neuroblastoma and was a significant predictive factor for adverse outcome in univariate analysis and in multivariate analysis. Expand
Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations
TLDR
It is concluded that besides monosomic short arm deletions, imbalance of 1p36 is a strong marker of a poor prognosis in neuroblastoma and not necessarily associated with MYCN amplification and LOH. Expand
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification
TLDR
This study provides further evidence that Stage 4 neuroblastoma with 11q deletions represent a distinct genetic subgroup that typically shows no MYCN‐amplification nor 1p deletion and shows that neuroblastomas with 12q deletion also often present 3p deletion. Expand
Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis
TLDR
It is concluded that chromosome 11q loss defines a biologically distinct group of tumours without MYCN amplification that appear to have potential for aggressive metastatic growth. Expand
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
TLDR
The hypothesis that a tumor suppressor gene mapping within 11q23.3 is commonly inactivated during the malignant evolution of a large subset of neuroblastomas, especially those with unamplified MYCN is supported. Expand
Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma.
TLDR
The applicability of CGH in studies on the genomic changes in pediatric malignancies is demonstrated, adding weight to the argument of multiple elements with oncogenic and/or tumor suppressor potential being involved in the aggressive phenotype of poor-risk neuroblastoma. Expand
An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas.
TLDR
Findings suggest that the increased NM23H1 copy number may be a predictor for poor prognosis, independent of LOH on 1p, and probably also of MYCN amplification. Expand
COMPARATIVE GENOMIC HYBRIDIZATION (CGH) ANALYSIS OF NEUROBLASTOMAS—AN IMPORTANT METHODOLOGICAL APPROACH IN PAEDIATRIC TUMOUR PATHOLOGY
TLDR
Comparative genomic hybridization was applied to 35 neuroblastomas to obtain a global view of genetic imbalances and shows that CGH is a sensitive method for the detection of all prognostically relevant genetic alterations in neuroblastoma and considerably simplifies the Detection of these alterations. Expand
...
1
2
3
...